Cargando…
Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS). Objective and Methods: The sNfL levels and MOG-Abs were measured by...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635987/ https://www.ncbi.nlm.nih.gov/pubmed/34867740 http://dx.doi.org/10.3389/fneur.2021.754518 |
_version_ | 1784608439659397120 |
---|---|
author | Simone, Marta Palazzo, Claudia Mastrapasqua, Mariangela Bollo, Luca Pompamea, Francesco Gabellone, Alessandra Marzulli, Lucia Giordano, Paola De Giacomo, Andrea Frigeri, Antonio Ruggieri, Maddalena Margari, Lucia |
author_facet | Simone, Marta Palazzo, Claudia Mastrapasqua, Mariangela Bollo, Luca Pompamea, Francesco Gabellone, Alessandra Marzulli, Lucia Giordano, Paola De Giacomo, Andrea Frigeri, Antonio Ruggieri, Maddalena Margari, Lucia |
author_sort | Simone, Marta |
collection | PubMed |
description | Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS). Objective and Methods: The sNfL levels and MOG-Abs were measured by ultrasensitive single-molecule array and cell-based assay in a cohort of 37 children with ADS and negativity for serum anti-aquaporin 4 (AQP4) antibodies. The sNfL levels were compared in MOG-Ab+/MOG-Ab– and in two subgroups MOG-Ab+ with/without encephalopathy. Results: About 40% ADS resulted in MOG-Ab+. MOG-Ab+ were younger at sampling (median = 9.8; range = 2.17–17.5 vs. 14.7/9–17; p = 0.002) with lower frequency of cerebrospinal fluid oligoclonal bands positivity (27% vs. 70%; p = 0.013) compared to MOG-Ab–. About 53% of MOG-Ab+ presented encephalopathy at onset, 1/22 of MOG-Ab– (p = 0.0006). Higher sNfL levels (p = 0.0001) were found in MOG-Ab+ (median/range = 11.11/6.8–1,129) and MOG-Ab– (median/range = 11.6/4.3–788) compared to age-matched controls (median/range = 2.98/1–4.53), without significant difference. MOG-Ab+ with encephalopathy resulted significantly younger at sampling (median/range: 4.5/2.17–11.17 vs. 14.16/9.8–17.5; p = 0.004), had higher sNfL levels (median/range:75.24/9.1–1,129 vs. 10.22/6.83–50.53; p = 0.04), and showed a trend for higher MOG-Ab titer (0.28/0.04–0.69 vs. 0.05/0.04–0.28; p = 0.1) in comparison to those without encephalopathy. Discussion: We confirmed high sNfL levels in pediatric ADS independently from the MOG-Ab status. Encephalopathy at onset is associated more frequently with MOG Ab+ children with higher sNfL levels and MOG titer. These findings suggest a role of acute demyelination in association with axonal damage in the pathogenesis of encephalopathy in pediatric ADS. |
format | Online Article Text |
id | pubmed-8635987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86359872021-12-02 Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes Simone, Marta Palazzo, Claudia Mastrapasqua, Mariangela Bollo, Luca Pompamea, Francesco Gabellone, Alessandra Marzulli, Lucia Giordano, Paola De Giacomo, Andrea Frigeri, Antonio Ruggieri, Maddalena Margari, Lucia Front Neurol Neurology Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS). Objective and Methods: The sNfL levels and MOG-Abs were measured by ultrasensitive single-molecule array and cell-based assay in a cohort of 37 children with ADS and negativity for serum anti-aquaporin 4 (AQP4) antibodies. The sNfL levels were compared in MOG-Ab+/MOG-Ab– and in two subgroups MOG-Ab+ with/without encephalopathy. Results: About 40% ADS resulted in MOG-Ab+. MOG-Ab+ were younger at sampling (median = 9.8; range = 2.17–17.5 vs. 14.7/9–17; p = 0.002) with lower frequency of cerebrospinal fluid oligoclonal bands positivity (27% vs. 70%; p = 0.013) compared to MOG-Ab–. About 53% of MOG-Ab+ presented encephalopathy at onset, 1/22 of MOG-Ab– (p = 0.0006). Higher sNfL levels (p = 0.0001) were found in MOG-Ab+ (median/range = 11.11/6.8–1,129) and MOG-Ab– (median/range = 11.6/4.3–788) compared to age-matched controls (median/range = 2.98/1–4.53), without significant difference. MOG-Ab+ with encephalopathy resulted significantly younger at sampling (median/range: 4.5/2.17–11.17 vs. 14.16/9.8–17.5; p = 0.004), had higher sNfL levels (median/range:75.24/9.1–1,129 vs. 10.22/6.83–50.53; p = 0.04), and showed a trend for higher MOG-Ab titer (0.28/0.04–0.69 vs. 0.05/0.04–0.28; p = 0.1) in comparison to those without encephalopathy. Discussion: We confirmed high sNfL levels in pediatric ADS independently from the MOG-Ab status. Encephalopathy at onset is associated more frequently with MOG Ab+ children with higher sNfL levels and MOG titer. These findings suggest a role of acute demyelination in association with axonal damage in the pathogenesis of encephalopathy in pediatric ADS. Frontiers Media S.A. 2021-11-11 /pmc/articles/PMC8635987/ /pubmed/34867740 http://dx.doi.org/10.3389/fneur.2021.754518 Text en Copyright © 2021 Simone, Palazzo, Mastrapasqua, Bollo, Pompamea, Gabellone, Marzulli, Giordano, De Giacomo, Frigeri, Ruggieri and Margari. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Simone, Marta Palazzo, Claudia Mastrapasqua, Mariangela Bollo, Luca Pompamea, Francesco Gabellone, Alessandra Marzulli, Lucia Giordano, Paola De Giacomo, Andrea Frigeri, Antonio Ruggieri, Maddalena Margari, Lucia Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes |
title | Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes |
title_full | Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes |
title_fullStr | Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes |
title_full_unstemmed | Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes |
title_short | Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes |
title_sort | serum neurofilament light chain levels and myelin oligodendrocyte glycoprotein antibodies in pediatric acquired demyelinating syndromes |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635987/ https://www.ncbi.nlm.nih.gov/pubmed/34867740 http://dx.doi.org/10.3389/fneur.2021.754518 |
work_keys_str_mv | AT simonemarta serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT palazzoclaudia serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT mastrapasquamariangela serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT bolloluca serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT pompameafrancesco serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT gabellonealessandra serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT marzullilucia serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT giordanopaola serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT degiacomoandrea serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT frigeriantonio serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT ruggierimaddalena serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes AT margarilucia serumneurofilamentlightchainlevelsandmyelinoligodendrocyteglycoproteinantibodiesinpediatricacquireddemyelinatingsyndromes |